查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848813

葛瑞夫兹氏病市场按诊断、治疗类型、年龄层、给药途径和分销管道划分－2025-2032 年全球预测

Graves Disease Market by Diagnosis, Treatment Type, Age Group, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，葛瑞夫兹氏病市场规模将成长至 10.1986 亿美元，复合年增长率为 5.97%。

主要市场统计数据
基准年2024年 6.4122亿美元
预计2025年 6.772亿美元
预测年份：2032年 10.1986亿美元
复合年增长率（%） 5.97%

简洁的临床和策略概述表葛瑞夫兹氏病是一种多学科的医疗保健挑战，需要综合诊断和量身定制的治疗途径

葛瑞夫兹氏病是一种复杂的自体免疫甲状腺疾病，其全身性影响远远超出了内分泌临床的范围。临床上，此病的特征是由针对甲状腺刺激素受体的刺激性抗体引起的甲状腺功能亢进，但其影响是多方面的，会影响心血管健康、眼科功能、代谢状态和患者生活品质。准确的诊断和及时的治疗性介入对于降低发病率、预防长期併发症以及优化不同患者群体的功能结果至关重要。因此，包括诊断实验室、製药商、医疗保健提供者、付款人和患者权益团体在内的相关人员越来越认识到需要整合的护理途径，强调精准诊断、个人化治疗选择和持续的后续护理。

在这种临床环境下，医疗格局正在迅速演变。改进的免疫检测、影像技术和数位健康平台正在重塑诊断工作流程，包括生物目标和复杂的放射性碘通讯协定在内的治疗创新正在改变治疗流程，支付方也在重新调整覆盖框架，以反映基于结果的优先事项。鑑于这些多方面的变化，领导者必须综合临床证据、监管趋势和营运现实，以调整优先考虑以患者为中心的治疗策略，同时保持财务责任。本引言将重点放在持续存在的临床挑战以及医疗服务、诊断和治疗创新领域转型改善的机会，为后续分析组装。

诊断进展、治疗方法创新和医疗服务转型将重塑护理途径和相关人员合作

在过去的几年中，由于诊断、治疗方案和医疗保健提供模式的进步，葛瑞夫兹氏病的检测、监测和治疗方法发生了变革性的变化。随着 TSH 受体抗体血清学检测更加灵敏和特异性，以及成像方式更加复杂，诊断准确性得到了提高，使临床医生能够更有效地对患者进行分层并减少诊断的不确定性。同时，治疗模式也在不断发展。虽然抗甲状腺药物和放射性碘治疗仍然是主要治疗方法，但人们对有针对性的免疫调节方法和个人化给药策略的兴趣日益浓厚，以减少过度治疗和不利事件。这些临床变化伴随着更广泛的系统级转变，包括将远端医疗整合到内分泌追踪中、远端监测甲状腺功能测试以及支持药物依从性和症状追踪的数位工具。

同时，监管和报销环境正在根据证明标靶诊断和治疗价值的证据进行调整，鼓励专科中心和一些医疗系统儘早采用精准医疗工具。由于相关人员力求确保放射性药物和检测试剂等关键投入，供应链的韧性和本地製造能力也变得越来越重要。总而言之，这些转变将推动一个更精细的生态系统，在这个生态系统中，临床医生、诊断开发人员和治疗方法创新者将携手合作，提供循证、可扩展且永续的以患者为中心的医疗服务。

对 2025 年关税对医用同位素、诊断试剂和医疗设备采购的影响进行策略性评估，并进行必要的调整以确保临床连续性。

2025年《政策与贸易发展报告》引入了新的关税措施，这些措施对与葛瑞夫兹氏病治疗相关的医疗投入产生了微妙的影响。影响医用同位素、专用诊断剂和某些医疗设备进口的关税调整，增加了医院和实验室采购的复杂性。因此，采购团队在采购促甲状腺激素受体检测试剂、用于治疗和摄取研究的放射性碘以及超音波和核医学设备时，必须应对成本结构的变化、供应商合约的更新以及潜在的前置作业时间波动。这些营运影响促使服务供应商重新评估供应商多元化，增加关键项目的库存缓衝，并寻求长期采购协议，以保护临床服务免受短期贸易波动的影响。

此外，关税主导的采购转变正在加速考虑国内生产方案和区域供应商网络，以降低跨境不确定性带来的风险。卫生系统和诊断实验室正在评估本地製造外包和集中供应安排，以保持医疗服务的连续性。重要的是，监管机构和相关人员正密切关注其对医疗可近性的影响。如果关税增加了提供某些诊断测试或治疗的成本，相关人员可能需要与付款人合作，调整报销政策，或探索在保持临床疗效的同时控製成本的替代医疗模式。应对这些挑战需要跨职能规划、积极的相关人员参与以及基于场景的营运方案。

综合細項分析将诊断方式、治疗方法、患者群体、配送路线和分销管道与可操作的临床和商业性优先事项联繫起来

此细分为理解葛瑞夫兹氏病的异质性临床路径和商业性动态提供了分析立足点。根据诊断，市场研究涵盖血液检测、影像检查和身体检查。血液检测进一步细分为游离4碘甲状腺素和T3水平、甲状腺刺激素(TSH) 水平和TSH受体抗体，而影像检查包括放射性碘摄取试验和甲状腺超音波。这些诊断区别非常重要，因为它们可以作为临床决策点，区分抗体介导的甲状腺功能亢进与其他病因，确定基于影像学定位的必要性，并指导监测强度。

从治疗角度来看，按治疗类型细分可区分抗甲状腺药物、 β阻断剂和放射性碘治疗，反映出不同的疗效、安全性和监测要求，这些要求会影响采购、报销和患者教育计画。按成人、老年人和儿童年龄组细分可突显临床表现、併发症负担和治疗耐受性的差异，进而影响临床指引和治疗优先顺序。依给药途径（静脉注射与口服）细分可捕捉医疗环境、给药基础设施和依从性考量的差异。最后，按分销管道（医院药房、线上药房和零售药房）细分会影响取得、配药工作流程和病患支援服务。结合这些细分视角，可以明确临床需求、交付机制和机会的交集，为诊断开发商、治疗药物製造商和医疗保健提供者提供量身定制的策略。

从区域角度检验医疗保健基础设施、法规环境和获取动态如何影响全球市场的诊断采用和治疗交付

区域动态显着影响着葛瑞夫兹氏病的治疗传递和技术创新的采用，美洲、欧洲、中东和非洲以及亚太地区呈现出明显的区域动态变化模式。在美洲，强大的诊断基础设施和一体化的专家网络促进了先进检测方法和多学科诊所的早期应用。然而，都市区/服务欠缺地区之间存在差异，因此需要係统层面的努力来扩大可近性和基于远端医疗的监测。在欧洲、中东和非洲，多样化的法律规范和异质的报销环境决定了新诊断和新治疗方法惠及患者的速度，而成熟的专业中心通常充当最佳实践方案和临床研究合作的中心。重要的是，许多国家医疗保健系统强调以指南主导的护理和基于价值的报销，从而影响了高成本创新的采用曲线。

医疗保健基础设施的快速投资、诊断能力的提升以及临床研究活动的扩展，正在加速亚太地区新型诊断和治疗方法的引入，但供应链集中度和区域製造限制可能会影响放射性药物和专用试剂的可得性。由于该地区内分泌疾病的盛行率、人口年龄结构和内分泌科医生的可及性存在差异，因此需要采取针对具体情况的策略，例如在某些市场开展公共卫生计画和医疗服务提供者教育宣传活动，在其他市场开展有针对性的报销合作，以及在跨境依赖程度较高的地区开展旨在增强供应链韧性的商业投资。这些区域洞察凸显了需要采取因地制宜的策略，以平衡临床优先事项与系统能力和政策现实。

企业优先事项的影响分析，强调诊断创新、治疗差异化、供应链稳健性以及持续影响的综合商业化策略

葛瑞夫兹氏病生态系中的企业策略正围绕着几个一致的优先事项：提高诊断准确性、优化治疗安全性和有效性，以及加强供应链和商业化能力。诊断公司正在投资高灵敏度的促甲状腺激素受体免疫测量，以及将血清学结果与影像数据关联起来以支持临床医生决策的整合平台。製药和生物技术开发公司正在寻求差异化的抗甲状腺药物、更安全的放射性碘治疗给药方案以及针对潜在自体免疫机制的生物製药，这促使临床研究中心和研发公司之间建立了许多合作伙伴关係，以加速转化途径。

在商业性，各公司专注于透过多种分销策略扩大药品供应，包括与医院药房合作、专业分销协议和数位配药管道。他们还在实施生产规模扩大和供应品质提升计划，以满足放射性药物和试剂製造的独特需求。此外，与诊断实验室和医疗系统的策略合作伙伴关係能够收集真实世界证据，以支持报销申请。此外，各公司正在投资患者支持和依从性项目，以减少治疗中断并改善临床疗效。总而言之，这些公司的优先事项凸显了向整合解决方案的转变，这些解决方案将诊断、治疗和服务整合在一起，从而为患者照护带来可衡量的改善。

为领导者提供实用的策略倡议，整合诊断准确性、供应链弹性、付款人参与度和患者访问模式，以推动临床和商业性成功

行业领导者必须采取积极主动、以患者为中心的方法，在利用临床进展的同时降低营运风险。首先，他们将投资于整合诊断生态系统，支援采用高度特异性的检测和影像工作流程，以实现准确的患者分层并减少诊断延迟。此外，他们将优先制定强调不同年龄层安全性和耐受性的治疗策略，同时将资源分配给能够产生比较有效性和真实世界证据以支持付款方论点的临床项目。其次，他们将透过供应商多元化、区域製造伙伴关係以及放射性药物和检测试剂等关键投入的库存管理实践来增强供应链的韧性，从而降低贸易中断和关税波动带来的脆弱性。

第三，透过混合配送和照护模式扩大患者可近性，将医院服务与远端医疗支援的追踪和药房药物配送结合。这包括与药房和数位健康平台合作，以提高依从性和监测能力。第四，儘早与监管机构和付款方进行透明的沟通，使临床开发与循证要求保持一致，并在适当情况下考虑基于价值的合约。最后，投资于内分泌科、核医和初级保健领域的劳动力发展，以确保符合指南的管理，并促进新诊断和治疗方法的采用。实施这些建议将有助于组织在技术创新的采用与营运永续性和改善患者预后之间取得平衡。

透明且可复製的混合方法研究框架，结合系统文献综述、专家访谈和数据三角测量，以确保临床和操作有效性

该研究方法将严格的二次证据审查与有针对性的原始资料收集相结合，以确保分析的稳健性和临床相关性。二次研究系统地回顾了同行评审文献、临床指南、监管文件和供应商技术规范，以建立关于病理学、诊断技术和治疗方法，以了解第一线实践、未满足的需求和实施障碍。数据三角检验对资讯来源的研究结果进行了交叉检验，并透过后续专家咨询和敏感性检查解决了差异。

调查方法保障措施包括：明确的临床试验和产品评估纳入和排除标准、透明的访谈通讯协定和受访者角色记录，以及对专家见解进行定性编码以识别重复出现的主题。地域覆盖范围确保了均衡的市场代表性，以反映医疗保健服务和监管格局。该研究也承认其局限性，包括不断变化的临床证据和不同地区数据可用性的潜在差异，并建议定期更新并针对优先子主题进行有针对性的初步研究。总体而言，该调查方法强调可重复性、同侪检验以及对参与葛瑞夫兹氏病治疗和商业策略的相关人员的实际意义。

简洁、全面的分析，重点在于诊断和治疗方面的进展，以及需要采取协调策略行动的供应链和政策挑战

这项分析强调，葛瑞夫兹氏病的管理正处于曲折点，改进的诊断方法、创新的治疗方法方案和切实可行的营运规划将塑造未来的治疗标准。血清学检测和影像技术的进步使得诊断更早、更准确成为可能，不断发展的治疗方法方案和护理模式有望提高安全性并带来以患者为中心的治疗效果。然而，这些机会也与系统性挑战并存，包括供应链脆弱性、与关税相关的采购复杂性以及区域差异化的采用模式，需要我们采取有针对性的策略性应对措施。

摘要，那些能够将临床开发与营运约束相结合、投资于弹性供应和分销网络、并积极与相关人员和监管机构合作的相关人员，将最有能力将科学进步转化为切实的患者利益。重视整合护理路径、证据生成和可扩展的交付模式，将加速创新技术的采用，从而改善葛瑞夫兹氏病病患者的生活质量，同时维持永续的组织绩效。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 采用针对 B 细胞调节的生物目标疗法治疗难治性疾病
  • 穿戴式甲状腺功能监测设备的整合可实现即时 TSH 追踪和病人参与
  • 扩展的远距内分泌平台促进葛瑞夫兹氏病病患者的远距离诊断和治疗协调
  • 新型小分子促甲状腺激素受体拮抗剂获监理机关核准，扩大非侵入性治疗选择
  • 增加抗甲状腺药物与免疫调节剂的联合治疗通讯协定，以降低復发率
  • 以患者为中心的数位健康应用程式的出现，支持葛瑞夫兹氏病的症状追踪和药物依从性
  • 高强度聚焦超音波作为葛瑞夫兹氏病眼疾治疗非手术替代方法的临床应用

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章葛瑞夫兹氏病市场（按诊断）

  • 血液检查
    • 游离4碘甲状腺素和 T3 水平
    • 甲状腺刺激素（TSH）水平
    • TSH受体抗体（TSH-RAb）
  • 影像检查
    • 放射性碘的吸收
    • 甲状腺超音波
  • 身体检查

第九章葛瑞夫兹氏病市场（依治疗类型）

  • 抗甲状腺药物
  • β受体阻断剂
  • 放射性碘治疗

第 10 章葛瑞夫兹氏病市场（按年龄组）

  • 成人
  • 老年人
  • 孩子们

第11章葛瑞夫兹氏病市场按管理途径

  • 静脉
  • 口服

第 12 章葛瑞夫兹氏病市场按分销管道划分

  • 医院药房
  • 网路药局
  • 零售药局

第十三章葛瑞夫兹氏病市场：按地区

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章葛瑞夫兹氏病市场：按组

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章葛瑞夫兹氏病市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • AdvanceCor GmbH
    • Cadila Pharmaceuticals Limited
    • CORONA Remedies Limited
    • Daxia Healthcare Pvt Ltd.
    • Eris Lifesciences Ltd
    • F. Hoffmann-La Roche Ltd.
    • Immunovant, Inc. by Roivant Sciences Ltd.
    • LGM Pharma
    • Macleods Pharmaceuticals Ltd.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Salvavidas Pharmaceutical Pvt. Ltd.
    • Siemens Healthineers AG
    • Steris Healthcare Pvt Ltd
    • Sun Pharmaceutical Industries Ltd
    • Synmedic Laboratories by Dhanuka Laboratories Limited
    • Teva Pharmaceutical Industries Ltd.
    • Thermo Fisher Scientific Inc.
    • Wellona Pharma
Product Code: MRR-42653751EADD

The Graves Disease Market is projected to grow by USD 1,019.86 million at a CAGR of 5.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 641.22 million
Estimated Year [2025] USD 677.20 million
Forecast Year [2032] USD 1,019.86 million
CAGR (%) 5.97%

A concise clinical and strategic overview that frames Graves disease as a multidisciplinary healthcare challenge demanding integrated diagnostics and tailored therapeutic pathways

Graves disease represents a complex autoimmune thyroid disorder with systemic implications that extend far beyond endocrinology clinics. Clinically, it is characterized by hyperthyroidism driven by stimulating antibodies against the thyroid-stimulating hormone receptor, but its impact is multidisciplinary-affecting cardiovascular health, ophthalmic function, metabolic status, and patient quality of life. Accurate diagnosis and timely therapeutic intervention are essential to reduce morbidity, prevent long-term complications, and optimize functional outcomes for diverse patient populations. Consequently, stakeholders across diagnostic labs, pharmaceutical manufacturers, providers, payers, and patient advocacy groups increasingly recognize the need for integrated care pathways that emphasize precision diagnostics, individualized treatment selection, and continuity of follow-up care.

Against this clinical backdrop, the landscape is evolving rapidly: improvements in immunoassays, imaging techniques, and digital health platforms are reshaping diagnostic workflows; therapeutic innovation including targeted biologics and refined radioiodine protocols is altering treatment algorithms; and payers are recalibrating coverage frameworks to reflect outcomes-based priorities. Given this multifaceted shift, leaders must synthesize clinical evidence, regulatory developments, and operational realities to adapt strategies that prioritize patient-centric outcomes while maintaining fiscal responsibility. This introduction frames the subsequent analysis by highlighting both the persistent clinical challenges and the opportunities for transformative improvement across care delivery, diagnostics, and therapeutic innovation.

An exploration of diagnostic advances, therapeutic innovation, and healthcare delivery transformation reshaping care pathways and stakeholder collaborations

The last several years have seen transformative shifts in how Graves disease is detected, monitored, and treated, driven by advances in diagnostics, therapeutic options, and healthcare delivery models. Diagnostic precision has improved through more sensitive and specific serological assays for TSH receptor antibodies and refined imaging modalities, enabling clinicians to stratify patients more effectively and reduce diagnostic uncertainty. Simultaneously, therapeutic paradigms are evolving: while antithyroid medications and radioiodine therapy remain mainstays, there is accelerating interest in targeted immunomodulatory approaches and personalized dosing strategies that reduce overtreatment and adverse events. These clinical changes are accompanied by broader system-level shifts, including the integration of telemedicine into endocrine follow-up, remote monitoring of thyroid function tests, and digital tools that support medication adherence and symptom tracking.

In parallel, regulatory and reimbursement environments are adapting to evidence demonstrating value in targeted diagnostics and therapies, prompting earlier adoption of precision tools in specialist centers and select health systems. Supply chain resilience and localized manufacturing capacity have also risen in importance, as stakeholders aim to secure critical inputs such as radiopharmaceuticals and assay reagents. Collectively, these shifts are driving a more nuanced ecosystem in which clinicians, diagnostics developers, and therapeutic innovators collaborate to deliver patient-centered care pathways that are evidence-informed, scalable, and sustainable.

A strategic assessment of 2025 tariff effects on medical isotope, diagnostic reagent, and device procurement and the operational adjustments required to protect clinical continuity

Policy and trade developments in 2025 introduced new tariff measures that have nuanced implications for medical inputs relevant to Graves disease care. Tariff adjustments affecting imports of medical isotopes, specialized diagnostic reagents, and certain medical devices have raised procurement complexity for hospitals and laboratories. As a result, purchasing teams must navigate altered cost structures, updated supplier contracts, and potential lead-time variability when acquiring reagents for TSH receptor assays, radioactive iodine supplies for therapy and uptake studies, and ultrasound and nuclear medicine equipment. These operational impacts have prompted service providers to reassess vendor diversification, increase inventory buffers for critical items, and pursue longer-term purchasing agreements to insulate clinical services from short-term trade fluctuations.

Moreover, tariff-driven procurement shifts are accelerating consideration of domestic production options and regional supplier networks to reduce exposure to cross-border uncertainties. Health systems and diagnostic labs are increasingly evaluating local contract manufacturing and collaborative supply arrangements to maintain continuity of care. Importantly, regulators and payers are mindful of access implications; where tariffs raise the cost of delivering specific diagnostic tests or therapies, stakeholders may need to work with payers to adjust reimbursement policies or explore alternative care models that preserve clinical outcomes while containing costs. Transitioning through these challenges requires cross-functional planning, proactive stakeholder engagement, and scenario-based operational playbooks to ensure patient access is maintained while organizations adapt to evolving trade realities.

An integrative segmentation analysis linking diagnostic modalities, therapeutic approaches, patient cohorts, delivery routes, and distribution channels to actionable clinical and commercial priorities

Segmentation provides the analytical scaffolding to understand heterogeneous clinical pathways and commercial dynamics in Graves disease, beginning with diagnostic modalities. Based on diagnosis, the market is examined across blood tests, imaging tests, and physical examination; blood tests are further delineated into Free T4 and T3 levels, thyroid-stimulating hormone (TSH) levels, and TSH receptor antibodies, while imaging tests include radioactive iodine uptake studies and thyroid ultrasound. These diagnostic distinctions matter because they drive clinical decision points-differentiating antibody-mediated hyperthyroidism from other etiologies, defining the need for imaging-based localization, and informing the intensity of monitoring.

From a treatment perspective, segmentation by treatment type distinguishes antithyroid medications, beta-blockers, and radioactive iodine therapy, reflecting different efficacy, safety, and monitoring requirements that influence procurement, reimbursement, and patient education programs. Age group segmentation across adult, elderly, and pediatric cohorts highlights variability in presentation, comorbidity burden, and treatment tolerability, which in turn affects clinical guidelines and therapeutic prioritization. Segmentation by route of administration-intravenous versus oral-captures differences in care setting, administration infrastructure, and adherence considerations. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies influences access, dispensing workflows, and patient support services. Taken together, these segmentation lenses enable tailored strategies for diagnostics developers, therapeutics manufacturers, and healthcare providers by clarifying where clinical needs, delivery mechanisms, and commercial opportunities intersect.

A region-by-region examination of healthcare infrastructure, regulatory environments, and access dynamics shaping diagnostic adoption and therapeutic delivery across global markets

Regional dynamics exert profound influence on care delivery and innovation adoption for Graves disease, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust diagnostic infrastructure and integrated specialist networks facilitate early adoption of advanced assays and multidisciplinary clinics; yet disparities persist between urban centers and rural or underserved communities, prompting system-level initiatives to expand access and telehealth-enabled monitoring. In Europe, Middle East & Africa, varied regulatory frameworks and heterogeneous reimbursement environments shape the pace at which new diagnostics and therapies reach patients, while established specialty centers often serve as hubs for best-practice protocols and clinical research collaborations. Importantly, national health systems in many countries emphasize guideline-driven care and value-based reimbursement, affecting adoption curves for higher-cost innovations.

Across Asia-Pacific, rapid investment in healthcare infrastructure, increasing diagnostic capacity, and expanding clinical research activity are accelerating uptake of novel diagnostics and therapeutic options, although supply chain concentration and regional manufacturing constraints can affect availability of radiopharmaceuticals and specialized reagents. Throughout all regions, differences in prevalence, population age structures, and access to endocrinology specialists demand context-specific strategies: public health programs and provider education campaigns in some markets, targeted reimbursement engagement in others, and operational investments in supply chain resilience where cross-border dependencies are pronounced. These regional insights highlight the need for geographically attuned approaches that balance clinical priorities with system capabilities and policy realities.

An analysis of corporate priorities emphasizing diagnostic innovation, therapeutic differentiation, supply chain robustness, and integrated commercialization strategies for sustained impact

Company strategies in the Graves disease ecosystem are converging on several consistent priorities: advancing diagnostic precision, optimizing therapeutic safety and efficacy, and strengthening supply chain and commercialization capabilities. Diagnostic firms are investing in higher-sensitivity immunoassays for TSH receptor antibodies and in integrated platforms that link serology results with imaging data to support clinician decision-making. Pharmaceutical and biotech developers are pursuing differentiated antithyroid agents, safer dosing regimens for radioiodine therapy, and biologic candidates that target underlying autoimmune mechanisms, with many partnerships forming between clinical research centers and developers to accelerate translational pathways.

Commercially, companies focus on expanding access through diversified distribution strategies that include hospital pharmacy partnerships, specialty distribution contracts, and digital dispensing channels. Manufacturing scale-up and quality-of-supply initiatives address the unique demands of radiopharmaceuticals and reagent production, while strategic collaborations with diagnostic labs and health systems enable real-world evidence collection to support reimbursement dossiers. Additionally, companies are investing in patient support and adherence programs that reduce treatment discontinuation and improve clinical outcomes. Taken together, these corporate priorities underscore a shift toward integrated solutions that combine diagnostics, therapeutics, and services to deliver measurable improvements in patient care.

Practical strategic initiatives for leaders to integrate diagnostic precision, supply chain resilience, payer engagement, and patient access models to drive clinical and commercial success

Industry leaders must adopt a proactive, patient-centered approach to capitalize on clinical advances while mitigating operational risks. First, invest in diagnostic ecosystem integration by supporting the adoption of high-specificity assays and imaging workflows that enable precise patient stratification and reduce diagnostic delay. Coupled with that, prioritize development of therapeutic strategies that emphasize safety and tolerability for diverse age cohorts, while allocating resources toward clinical programs that generate comparative effectiveness and real-world evidence to support payer discussions. Second, fortify supply chain resilience through supplier diversification, regional manufacturing partnerships, and inventory management practices for critical inputs such as radiopharmaceuticals and assay reagents, thereby reducing vulnerability to trade disruptions and tariff volatility.

Third, expand patient access via hybrid distribution and care models that blend hospital-based services with telehealth-enabled follow-up and pharmacy-based medication delivery. This includes partnering with pharmacies and digital health platforms to improve adherence and monitoring. Fourth, engage early and transparently with regulators and payers to align clinical development with evidentiary requirements and to explore value-based contracting where appropriate. Finally, invest in workforce training across endocrinology, nuclear medicine, and primary care to ensure guideline-concordant management and to accelerate uptake of emerging diagnostics and therapies. Implementing these recommendations will help organizations balance innovation adoption with operational sustainability and improved patient outcomes.

A transparent and reproducible mixed-methods research framework combining systematic literature review, expert interviews, and data triangulation to ensure clinical and operational validity

The research approach combines rigorous secondary evidence review with targeted primary data collection to ensure analytical robustness and clinical relevance. Secondary research entailed systematic review of peer-reviewed literature, clinical guidelines, regulatory documents, and vendor technical specifications to establish a comprehensive knowledge base on pathophysiology, diagnostic technologies, and therapeutic modalities. Primary research complemented this foundation through structured interviews with endocrinologists, nuclear medicine specialists, laboratory directors, pharmacists, and health system procurement leaders to capture frontline operational realities, unmet needs, and adoption barriers. Data triangulation ensured findings were cross-validated across sources, with discrepancies resolved through follow-up expert consultations and sensitivity checks.

Methodological safeguards included explicit inclusion and exclusion criteria for clinical studies and product assessments, transparent documentation of interview protocols and respondent roles, and qualitative coding of expert insights to identify recurrent themes. Geographic coverage targeted a balanced representation of markets to reflect variation in healthcare delivery and regulatory contexts. The study also acknowledges limitations, including the evolving nature of clinical evidence and potential variability in regional data availability, and recommends periodic updates and targeted primary studies for high-priority subtopics. Overall, the methodology emphasizes reproducibility, peer validation, and practical relevance for stakeholders involved in Graves disease care and commercial strategy.

A concise synthesis highlighting diagnostic and therapeutic progress alongside supply chain and policy challenges that require coordinated strategic action

This analysis underscores that Graves disease management is at an inflection point where diagnostic refinement, therapeutic innovation, and pragmatic operational planning converge to shape future standards of care. Improvements in serological assays and imaging techniques are enabling earlier, more accurate diagnosis, while evolving therapeutic options and care models offer the prospect of improved safety and patient-centered outcomes. However, these opportunities coexist with systemic challenges including supply chain vulnerabilities, tariff-related procurement complexities, and heterogeneous regional adoption patterns that require deliberate strategic responses.

In summary, stakeholders who align clinical development with real-world operational constraints, invest in resilient supply and distribution networks, and proactively engage payers and regulators will be best positioned to translate scientific advances into tangible patient benefits. Emphasizing integrated care pathways, evidence generation, and scalable delivery models will accelerate the adoption of innovations that improve quality of life for patients living with Graves disease while maintaining sustainable organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of targeted biologic therapies aiming at B-cell modulation for refractory Graves disease management
  • 5.2. Integration of wearable thyroid function monitoring devices enabling real time TSH tracking and patient engagement
  • 5.3. Expansion of teleendocrinology platforms facilitating remote diagnosis and treatment adjustments for Graves disease patients
  • 5.4. Regulatory approval of novel small molecule TSH receptor antagonists expanding non invasive treatment options
  • 5.5. Growth in combination therapy protocols merging antithyroid drugs with immunomodulators to reduce relapse rates
  • 5.6. Emergence of patient centric digital health applications supporting symptom logging and medication adherence in Graves disease
  • 5.7. Clinical adoption of high intensity focused ultrasound as a non surgical alternative for Graves ophthalmopathy management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Graves Disease Market, by Diagnosis

  • 8.1. Blood Tests
    • 8.1.1. Free T4 & T3 Levels
    • 8.1.2. Thyroid-stimulating Hormone (TSH) Levels
    • 8.1.3. TSH Receptor Antibodies (TSH-RAb)
  • 8.2. Imaging Tests
    • 8.2.1. Radioactive Iodine Uptake
    • 8.2.2. Thyroid Ultrasound
  • 8.3. Physical Examination

9. Graves Disease Market, by Treatment Type

  • 9.1. Antithyroid Medications
  • 9.2. Beta-Blockers
  • 9.3. Radioactive Iodine Therapy

10. Graves Disease Market, by Age Group

  • 10.1. Adult
  • 10.2. Elderly
  • 10.3. Pediatric

11. Graves Disease Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Graves Disease Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Graves Disease Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Graves Disease Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Graves Disease Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AdvanceCor GmbH
    • 16.3.3. Cadila Pharmaceuticals Limited
    • 16.3.4. CORONA Remedies Limited
    • 16.3.5. Daxia Healthcare Pvt Ltd.
    • 16.3.6. Eris Lifesciences Ltd
    • 16.3.7. F. Hoffmann-La Roche Ltd.
    • 16.3.8. Immunovant, Inc. by Roivant Sciences Ltd.
    • 16.3.9. LGM Pharma
    • 16.3.10. Macleods Pharmaceuticals Ltd.
    • 16.3.11. Merck KGaA
    • 16.3.12. Novartis AG
    • 16.3.13. Pfizer Inc.
    • 16.3.14. Salvavidas Pharmaceutical Pvt. Ltd.
    • 16.3.15. Siemens Healthineers AG
    • 16.3.16. Steris Healthcare Pvt Ltd
    • 16.3.17. Sun Pharmaceutical Industries Ltd
    • 16.3.18. Synmedic Laboratories by Dhanuka Laboratories Limited
    • 16.3.19. Teva Pharmaceutical Industries Ltd.
    • 16.3.20. Thermo Fisher Scientific Inc.
    • 16.3.21. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GRAVES DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 284. GCC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 285. GCC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 286. GCC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 287. GCC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 288. GCC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 289. GCC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GCC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GCC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GCC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GCC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. GCC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. GCC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. GCC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 320. BRICS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 321. BRICS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. BRICS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. BRICS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. BRICS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. BRICS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 326. BRICS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 327. BRICS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. BRICS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. G7 GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 332. G7 GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 333. G7 GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 334. G7 GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 335. G7 GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 336. G7 GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 337. G7 GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. G7 GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. G7 GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 340. G7 GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 341. G7 GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. G7 GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. G7 GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. G7 GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 345. NATO GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 346. NATO GRAVES DISEASE MARKET SIZE, BY COUNTR